Focused ultrasound developer Arrayus Technologies is promoting the completion of focused ultrasound treatment for breast cancer at Sunnybrook Health Sciences Centre in Toronto by 30 patients participating in a phase I prospective clinical trial using the company’s focused ultrasound platform.
The trial, led by Gregory Czarnota, MD, is evaluating the safety and potential of the Arrayus device to enhance tumor response to external beam radiation therapy. MR-guided focused ultrasound is delivered with microbubble therapy to enhance the therapeutic effects of radiation in patients with locally advanced breast cancer.
Arrayus’ focused ultrasound system uses proprietary technology and has a fully phased array, intuitive treatment planning tools, and real-time therapy monitoring. Its features enable clinicians to tailor treatments based on individual disease characteristics, the company advises.
The system received clearance from Health Canada in October 2024 for its use to ablate uterine fibroid tissue.
